Cadrenal Therapeutics, Inc. filed 3 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-10. Between them they name 4 people, with 2 appointments and 2 departures. Each change below is quoted from the filing and linked to it.
Every change, newest first
Reported
On July 7, 2026, James J. Ferguson III, Chief Medical Officer of Cadrenal Therapeutics, Inc. (the "Company"), advised the Board of Directors of the Company of his decision to resign from his position as Chief Medical Officer of the Company, effective July 31, 2026 (the "Separation Date").
Appointed: John P. Sharp, Chief Financial Officer
On June 25, 2026, the Board of Directors (the "Board") of Cadrenal Therapeutics, Inc. (the "Company") appointed John P. Sharp as Interim Chief Financial Officer of the Company.
Departing: Steven Zelenkofske, Director, effective 2026-06-30
On June 28, 2026, Steven Zelenkofske, a Class III member of the Board, notified the Company of his resignation from the Board, effective June 30, 2026.
Departing: Glynn Wilson, Director
Accordingly, on June 29, 2026, Dr. Glynn Wilson resigned as a Class I director.
Appointed: Quang X. Pham, Chief Financial Officer
Effective immediately after Mr. Szot's termination, the Company appointed Quang X. Pham, its Chief Executive Officer, as interim Chief Financial Officer and interim Principal Accounting Officer, to serve until a permanent Chief Financial Officer is appointed.
Cadrenal Therapeutics, Inc.'s funding history
Find people with the same kind of experience as the Chief Financial Officer at Cadrenal Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Cadrenal Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Cadrenal Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Cadrenal Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Cadrenal Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.